Latest Ratios: P/E Ratio -1.2x · EV/EBITDA N/A · ROE -109.2%. (2021–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Market Cap | $33M | $32M | — | — | — |
| Enterprise Value | $13M | $3M | — | — | — |
| P/E Ratio → | -1.16 | — | — | — | — |
| P/S Ratio | 13.32 | 8.86 | — | — | — |
| P/B Ratio | 0.99 | 0.75 | — | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| EV / Revenue | — | 0.84 | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Gross Margin | 1.1% | 1.1% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -1050.6% | -1050.6% | -12238.4% | -11803.3% | -225527.7% |
| Net Profit Margin | -1055.3% | -1055.3% | -16024.3% | -11838.6% | -343550.9% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| ROE | -109.2% | -109.2% | -131.5% | -63.8% | -48.2% |
| ROA | -48.4% | -48.4% | -65.2% | -43.7% | -36.4% |
| ROIC | -254.1% | -254.1% | -128.8% | -74.1% | -41.5% |
| ROCE | -60.6% | -60.6% | -63.0% | -50.3% | -26.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | -0.68 | -0.68 | -0.26 | -0.43 |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | -584.59 | -584.59 | -56.96 | -400.83 | -2.13 |
Net cash position: cash ($29M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Current Ratio | 2.67 | 2.67 | 1.30 | 1.23 | 3.46 |
| Quick Ratio | 2.67 | 2.67 | 1.30 | 1.23 | 3.46 |
| Cash Ratio | 1.95 | 1.95 | 1.06 | 0.88 | 3.42 |
| Asset Turnover | — | 0.04 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | 1044.75 | 1204.45 | 5578.03 | 2334.50 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $7M | $1M | $1M | $1M |
Clinical trial funding dependency
Based on reported figures, RADX trades at a price-to-sales ratio of 12.64, which appears to reflect a significant clinical-stage discount compared to commercial-stage peers, as the market struggles to price the long-term value of a diversified theranostic pipeline against current, non-recurring revenue streams.
The elevated P/S multiple suggests that investors are assigning value to the company's intellectual property and strategic partnerships rather than current operational output. This valuation remains highly sensitive to clinical trial readouts, as the lack of recurring revenue makes traditional earnings-based metrics inapplicable for assessing the firm's intrinsic worth.
As indicated by the company's financial profile, the reported gross margin of 1.08% and operating margin of -1050% underscore a pre-commercial cost structure where research and isotope procurement expenses vastly exceed the lumpy, milestone-driven revenue recognized in recent periods.
These margins are characteristic of an early-stage biotech firm and should not be interpreted as a failure of operational efficiency, but rather as the necessary cost of advancing a complex clinical pipeline. Investors should monitor for margin expansion only after the company transitions to a commercial-stage manufacturing model.
According to recent financial disclosures, the company's efficiency is currently constrained by the high capital intensity of its isotope procurement and clinical trial programs, which creates significant volatility in working capital and necessitates a reliance on external funding to maintain operational momentum.
The absence of a stable revenue base means that traditional efficiency ratios like asset turnover are currently distorted and provide little insight into long-term performance. The firm's ability to manage its cash conversion cycle is secondary to its success in meeting clinical milestones that trigger further partnership payments.
The price-to-sales ratio is frequently misapplied to RADX, as it obscures the reality that current revenue is derived from non-recurring milestone payments rather than sustainable product sales, potentially leading to an inaccurate assessment of the company's true commercial trajectory and underlying business value.
Analysts should instead focus on the cash burn rate relative to the remaining runway and the probability-weighted net present value of the clinical pipeline. Relying on P/S ratios in a pre-revenue context risks misinterpreting one-time accounting events as evidence of long-term operational growth.
Includes 30+ ratios · 4 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RADX stock.
Radiopharm Theranostics Limited's current P/E ratio is -1.2x. This places it at the 50th percentile of its historical range.
Radiopharm Theranostics Limited's return on equity (ROE) is -109.2%. The historical average is -88.2%.
Based on historical data, Radiopharm Theranostics Limited is trading at a P/E of -1.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Radiopharm Theranostics Limited has 1.1% gross margin and -1050.6% operating margin.